Catheter-based renal sympathetic denervation increased renal functional reserve in 71% of hypertensive patients at 3 months, with significant improvements in normal renal function and stage 2 CKD (p=0.01).
Observational (n=24)
Does catheter-based renal sympathetic denervation improve renal functional reserve in patients with essential hypertension?
Renal sympathetic denervation may improve renal functional reserve and reduce proteinuria in patients with essential hypertension, particularly those with early-stage chronic kidney disease.
p-value: p=0.01
Objective: To search the impact of catheter-based renal sympathetic denervation (RDN) on renal functional reserve (RFR) in patients with essential hypertension with normal renal function or chronic renal disease with an estimated glomerular filtration rate (eGFR) >=30 ml/min/1.73m2. Design and method: Patients with essential, uncontrolled hypertension either under antihypertensive treatment with at least one drug class or naive from antihypertensive treatment, with normal renal function or chronic kidney disease (CKD) up to stage IIIb (eGFR >=30 ml/min/1.73m2) are eligible for enrollment. RFR is estimated before and three months after RDN. In addition, the urine albumin/creatinine ratio (UACR) and 24-hour urine protein after 24-hour home urine collection are measured at the same time points. Results: Twenty-four patients were enrolled and completed three-month follow-up after RDN. Six patients had stage 2 CKD and 4 had stage 3 CKD. 96% of patients had microalbuminuria. At baseline, in 67% of patients RFR was below the normal value. Post-RDN, 50% of patients exhibited a reduction in 24-hour urine protein with a significant decrease observed in patients with stage 3 CKD (p=0.015). RFR increased in 71% of patients three months post-RDN, reaching statistical significance among those with normal renal function and stage 2 CKD (p=0.01).Conclusions: In this part of our protocol, there was a significant reduction of 24-hour urine protein in patients with stage 3 CKD. RFR increased in 71% of participants three months post-RDN, reaching statistical significance among those with normal renal function and stage 2 CKD. Patients are still enrolled and data on larger pool are anticipated.
Mavroudis et al. (Fri,) conducted a observational in Essential, uncontrolled hypertension with normal renal function or CKD up to stage IIIb (n=24). Catheter-based renal sympathetic denervation was evaluated on Renal functional reserve (RFR) and 24-hour urine protein (p=0.01). Catheter-based renal sympathetic denervation increased renal functional reserve in 71% of hypertensive patients at 3 months, with significant improvements in normal renal function and stage 2 CKD (p=0.01).